Trial site
Scottsdale Clinical Trials
Scottsdale, Arizona 85260, United StatesNot linked to an institution yet
- 13running trials
- 8closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 317 trials
- Phase 23 trials
- Status
- Completed7 trials
- Recruiting7 trials
- Active, not recruiting6 trials
- Terminated1 trial
- Lead sponsor
- Eli Lilly and Company3 trials
- Vertex Pharmaceuticals Incorporated3 trials
- Alumis Inc2 trials
- ModernaTX, Inc.2 trials
- Viridian Therapeutics, Inc.2 trials
- and 9 more
Running trials
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NCT07384975· Phase 2· Navigator Medicines, Inc.· Source
Contact: Associate Director, Clinical Operations
Recruiting
Study of DONQ52 in Active Celiac Disease
NCT07239336· Phase 2· Chugai Pharmaceutical· Source
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· Phase 3· Bristol-Myers Squibb· Source
Contact: Todd Dreitzler, Site 0432
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· Phase 3· Alumis Inc· Source
Active, not recruiting
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT06696443· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
NCT06625398· Phase 3· Viridian Therapeutics, Inc.· Source
Active, not recruiting
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
NCT06625411· Phase 3· Viridian Therapeutics, Inc.· Source
Active, not recruiting
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
NCT06334133· Phase 3· vTv Therapeutics· Source
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Recruiting
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418· Cleerly, Inc.· Source
Contact: Todd Dreitzler, MD
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
NCT06588283· Phase 3· Eli Lilly and Company· Source
Completed
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· Phase 3· Alumis Inc· Source
Completed
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
NCT06354660· Phase 3· Eli Lilly and Company· Source
Completed
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
NCT06178991· Phase 3· BioNTech SE· Source
Completed
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
NCT06097273· Phase 3· ModernaTX, Inc.· Source
Terminated
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
NCT06077773· Phase 2· Escient Pharmaceuticals, Inc· Source
Completed
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
NCT06060457· Phase 3· ModernaTX, Inc.· Source
Completed
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
NCT05899816· Phase 3· Amgen· Source
Report an error